C. Debieuvre

Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release

W. Poewe, O. Rascol, R. Hauser, 2014, Parkinson's disease.

Oxidation resistance of SiC/SiC micro and minicomposites with a highly crystallised BN interphase

F. Rebillat, R. Naslain, A. Guette, 1998 .

Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial

E. Tolosa, W. Poewe, O. Rascol, 2010, The Lancet Neurology.

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease

W. Poewe, O. Rascol, R. Hauser, 2014, European journal of neurology.

Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease

W. Poewe, O. Rascol, R. Hauser, 2010, Movement disorders : official journal of the Movement Disorder Society.

Efficacy and safety of duloxetine 60 mg once daily in the treatment of pain in patients with major depressive disorder and at least moderate pain of unknown etiology: a randomized controlled trial.

K. Demyttenaere, S. Brecht, J. Raskin, 2007, The Journal of clinical psychiatry.

Patient‐reported convenience of once‐daily versus three‐times‐daily dosing during long‐term studies of pramipexole in early and advanced Parkinson’s disease

W. Poewe, O. Rascol, A. Schapira, 2013, European journal of neurology.

P2.155 Simple overnight switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage

W. Poewe, O. Rascol, R. Hauser, 2009 .